Mejía Carmen, Navarro Samuel, Pellín Antonio, Ruíz Amparo, Castel Victoria, Llombart-Bosch Antonio
Department of Neurosciences, Institute of Cell Physiology, Universidad Nacional Autónoma de Mexico, Mexico City 04510, D.F. Mexico.
Oncol Rep. 2003 Jan-Feb;10(1):243-7.
Peripheral neuroblastic tumors (PNT), are heterogeneous neoplasms that include neuroblastoma (NB), ganglioneuroblastoma (GNB) and ganglioneuroma (GN) and present great biological heterogeneity. There are few reports analyzing PCNA and Ki-67 expression in PNT; however, controversy exists concerning the specificity of PCNA as a real proliferative marker. The objective of our study was to determine which of these cellular proliferation markers is more specific on cellular cycle and could contribute with more information on the cell cycle. We found that PCNA was expressed in NB unfavourable cases, with MYCN amplification and high mitosis-karyorrhexis-index (MKI). Whereas, Ki-67 showed statistical significance regarding cases unfavourable with intermediate and high MKI, aneuploid and stages 3 and 4. Survival showed that patients with tumor not expressing Ki-67 (MIB1) lived longer than those without PCNA (88.93 vs 74.05%). We conclude that Ki-67 expression permits reliable detection of the cellular proliferation neuroblastoma fraction and provides useful prognostic information when associated with other biological factors.
外周神经母细胞瘤（PNT）是一类异质性肿瘤，包括神经母细胞瘤（NB）、神经节神经母细胞瘤（GNB）和神经节瘤（GN），具有很大的生物学异质性。关于PNT中增殖细胞核抗原（PCNA）和Ki-67表达的分析报道较少；然而，关于PCNA作为真正增殖标志物的特异性存在争议。我们研究的目的是确定这些细胞增殖标志物中哪一种在细胞周期上更具特异性，并且能提供更多关于细胞周期的信息。我们发现PCNA在伴有MYCN扩增和高有丝分裂-核溶解指数（MKI）的NB不良病例中表达。而Ki-67在MKI为中度和高度、非整倍体以及3期和4期不良病例中具有统计学意义。生存情况显示，肿瘤不表达Ki-67（MIB1）的患者比不表达PCNA的患者活得更长（88.93%对74.05%）。我们得出结论，Ki-67表达能够可靠地检测神经母细胞瘤细胞增殖部分，并且与其他生物学因素相关时可提供有用的预后信息。
